STOCK TITAN

Centessa Pharmaceuticals Plc - CNTA STOCK NEWS

Welcome to our dedicated page for Centessa Pharmaceuticals Plc news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals Plc stock.

About Centessa Pharmaceuticals Plc

Centessa Pharmaceuticals Plc (Nasdaq: CNTA) is a clinical-stage biopharmaceutical company dedicated to discovering and developing transformational medicines for patients with significant unmet medical needs. Headquartered in Cambridge, Massachusetts, the company employs an innovative asset-centric research and development (R&D) model, supported by a centralized infrastructure and expert management team. This approach enables Centessa to advance a diverse portfolio of highly validated programs efficiently and effectively.

Core Business Areas

Centessa focuses on three primary therapeutic areas:

  • Sleep-Wake Disorders: The company is pioneering the development of orexin receptor 2 (OX2R) agonists, including its lead candidate, ORX750, for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and excessive daytime sleepiness (EDS) in neurological, neurodegenerative, and psychiatric conditions. These investigational therapies aim to address the underlying pathophysiology of orexin neuron loss, offering potential first-in-class and best-in-class solutions.
  • Immuno-Oncology: Centessa's proprietary LockBody® technology platform is designed to redefine cancer treatment by selectively targeting the tumor microenvironment (TME) while minimizing systemic toxicity. The platform's lead candidate, LB101, is a conditionally tetravalent bispecific monoclonal antibody currently in Phase 1/2a clinical trials.
  • Hemophilia: Although the company recently discontinued its SerpinPC program for hemophilia B to prioritize its orexin agonist franchise, this decision underscores Centessa's commitment to focusing resources on high-impact areas.

Innovative R&D Model

Centessa's asset-centric R&D model is a cornerstone of its strategy. Each program operates as a subsidiary, led by specialized teams with deep expertise in their respective fields. This structure allows the company to advance multiple programs simultaneously while leveraging centralized resources for operational efficiency. By focusing on highly validated targets, Centessa aims to de-risk its pipeline and accelerate the development of breakthrough therapies.

Competitive Landscape

Centessa operates in a competitive pharmaceutical landscape, where innovation and differentiation are critical. Its orexin agonist program competes with other emerging therapies targeting sleep-wake disorders, while the LockBody platform positions the company uniquely in the immuno-oncology space. By addressing significant unmet needs and leveraging cutting-edge technologies, Centessa aims to carve out a distinct market position.

Commitment to Patients and Shareholders

Centessa's mission is to deliver medicines that transform patient outcomes and establish new standards of care. The company is also committed to creating long-term value for shareholders by focusing on high-potential assets and maintaining a robust financial position. With a cash runway extending into mid-2027, Centessa is well-positioned to execute its clinical development plans and achieve multiple value-creating milestones.

Key Differentiators

  • Orexin Agonist Program: A pipeline of highly potent and selective OX2R agonists, including ORX750 and ORX142, targeting a broad spectrum of sleep-wake and neurological disorders.
  • LockBody Technology Platform: A novel approach to immuno-oncology that aims to enhance efficacy while reducing systemic toxicity.
  • Asset-Centric R&D Model: A unique structure that combines the agility of focused subsidiaries with the scalability of centralized operations.

Conclusion

Centessa Pharmaceuticals Plc represents a next-generation approach to biopharmaceutical innovation. By combining an asset-centric R&D model with cutting-edge technologies, the company is well-positioned to address some of the most challenging medical conditions. Its focus on transformational medicines underscores its commitment to improving patient outcomes and redefining treatment paradigms.

Rhea-AI Summary

Schrödinger (Nasdaq:SDGR) and Centessa Pharmaceuticals (Nasdaq:CNTA) announced an exclusive collaboration to discover novel therapeutics targeting the orexin-2 receptor (OX2R), relevant for sleep disorders like narcolepsy. This partnership marks the first large-scale application of Schrödinger's computational platform in orexin agonist development, leveraging Orexia’s structural biology capabilities. Orexia will manage preclinical research and commercialization, while Schrödinger will receive upfront payments and potential royalties on global sales. The collaboration aims to explore orexin agonists for various disorders characterized by excessive daytime sleepiness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
-
Rhea-AI Summary

Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed David Grainger, PhD, as its new Chief Innovation Officer, enhancing its executive leadership team. Dr. Grainger, a key advisor since the company's formation, will oversee scientific and research activities, shaping the development of therapeutic candidates. His appointment aligns with Centessa's goals for clinical and pre-clinical milestones. Previously, Dr. Grainger co-founded 28 biotech companies and has extensive experience in drug development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
management
-
Rhea-AI Summary

Centessa Pharmaceuticals has announced a $300 million financing agreement with Oberland Capital, significantly boosting its available capital to over $900 million. This funding will support the advancement of its clinical and pre-clinical programs and enable strategic business development. The financing structure includes interest-only senior secured notes for six years. The initial $75 million was funded on October 4, 2021, with further options for funding available. This strategic move comes after a positive Phase 2 trial readout and sets the stage for potential registrational studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
Rhea-AI Summary

Centessa Pharmaceuticals (Nasdaq: CNTA) announced positive topline results from the Phase 2a trial of SerpinPC, a treatment for severe hemophilia A and B. The study showed an 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% for spontaneous joint bleeds in the highest dose tested. The drug was found to be well-tolerated, with minimal adverse events reported. The company plans to initiate a global registrational program and will host a conference call to discuss findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
none
-
Rhea-AI Summary

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET. A live audio webcast will be available on the investor relations section of Centessa's website, with a replay accessible for 90 days post-event. Centessa focuses on bringing new medicines to patients through a specialized, asset-centric approach, targeting various therapeutic areas such as oncology and immunology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
conferences
-
Rhea-AI Summary

Centessa Pharmaceuticals (NASDAQ: CNTA) successfully completed an initial public offering (IPO), raising gross proceeds of $379.5 million to support its clinical and preclinical programs. The leadership team has been strengthened with key appointments in various executive roles. Financial results for Q2 2021 show a cash position of $613.8 million, enabling operations through the end of 2023. R&D expenses rose to $18.1 million due to an expanded portfolio, while net loss increased to $41.5 million or $0.65 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
Rhea-AI Summary

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 5:30 p.m. ET. The company focuses on developing new medicines through an asset-centric model, emphasizing specialized teams for diverse therapeutic areas, including oncology, hematology, and immunology. Centessa owns ten asset-centric companies, ranging from discovery to late-stage development, allowing for strategic resource allocation and shared infrastructure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
conferences
-
Rhea-AI Summary

Citi has been appointed by Centessa Pharmaceuticals to serve as the depositary bank for its American Depositary Receipt (ADR) program. Centessa's American Depositary Shares (ADSs) are listed on the Nasdaq under the symbol 'CNTA'. Dirk Jones from Citi expressed enthusiasm for supporting Centessa's ADR program and enhancing investor outreach through their global equity distribution network. Centessa aims to innovate the drug development process by applying an asset-centric R&D model across its ten subsidiaries, backed by centralized infrastructure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Summary

Centessa Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 2,475,000 American Depositary Shares (ADSs) at the IPO price of $20.00, raising total gross proceeds to $379.5 million. The IPO closing occurred on June 2, 2021, with the additional ADSs issued today. This offering reflects the firm's asset-centric model aimed at developing impactful medicines. Morgan Stanley, Goldman Sachs, Jefferies, and Evercore ISI managed the offering. A registration statement was declared effective by the SEC on May 27, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
Rhea-AI Summary

Centessa Pharmaceuticals announced the pricing of its initial public offering of 16,500,000 American Depositary Shares (ADSs) at $20.00 per ADS, totaling approximately $330 million in gross proceeds. The offering is expected to close on June 2, 2021, pending customary conditions, with shares trading on Nasdaq under the symbol "CNTA" starting May 28, 2021. The underwriters have a 30-day option to purchase an additional 2,475,000 ADSs. Morgan Stanley, Goldman Sachs, Jefferies, and Evercore ISI are managing the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Centessa Pharmaceuticals Plc (CNTA)?

The current stock price of Centessa Pharmaceuticals Plc (CNTA) is $11.68 as of April 4, 2025.

What is the market cap of Centessa Pharmaceuticals Plc (CNTA)?

The market cap of Centessa Pharmaceuticals Plc (CNTA) is approximately 1.6B.

What is Centessa Pharmaceuticals' business model?

Centessa employs an asset-centric R&D model, where each program operates as a subsidiary supported by centralized resources, enabling efficient and focused drug development.

What are Centessa's key therapeutic areas?

Centessa focuses on sleep-wake disorders, immuno-oncology, and previously hemophilia, with innovative programs like orexin receptor agonists and the LockBody® platform.

What is the purpose of Centessa's orexin agonist program?

The orexin agonist program aims to develop therapies for narcolepsy, idiopathic hypersomnia, and excessive daytime sleepiness by targeting the underlying pathophysiology of orexin neuron loss.

What is the LockBody technology platform?

The LockBody platform is designed to selectively target the tumor microenvironment in cancer, enhancing efficacy while minimizing systemic toxicity.

Why did Centessa discontinue its SerpinPC program?

Centessa discontinued SerpinPC to prioritize resources for its orexin agonist program, aligning with its focus on high-potential assets and evolving market needs.

What makes Centessa Pharmaceuticals unique?

Centessa's asset-centric R&D model, innovative orexin agonist program, and LockBody technology platform set it apart in the competitive biopharmaceutical landscape.

What is ORX750?

ORX750 is a highly potent and selective orexin receptor 2 (OX2R) agonist in clinical trials for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders.

What is Centessa's financial position?

Centessa has a cash runway extending into mid-2027, supporting its clinical development plans and multiple potential value-creating milestones.

What are Centessa's competitive advantages?

Centessa's competitive advantages include its asset-centric R&D model, differentiated orexin agonist pipeline, and the innovative LockBody platform for immuno-oncology.

What is Centessa's mission?

Centessa's mission is to deliver transformational medicines that improve patient outcomes and establish new standards of care.
Centessa Pharmaceuticals Plc

Nasdaq:CNTA

CNTA Rankings

CNTA Stock Data

1.65B
114.29M
1.29%
97.12%
4.14%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
ALTRINCHAM, CHESHIRE